Does OLAPARIB Cause Second primary malignancy? 52 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 52 reports of Second primary malignancy have been filed in association with OLAPARIB (Lynparza). This represents 0.3% of all adverse event reports for OLAPARIB.
52
Reports of Second primary malignancy with OLAPARIB
0.3%
of all OLAPARIB reports
12
Deaths
18
Hospitalizations
How Dangerous Is Second primary malignancy From OLAPARIB?
Of the 52 reports, 12 (23.1%) resulted in death, 18 (34.6%) required hospitalization, and 11 (21.2%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 52 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which OLAPARIB Alternatives Have Lower Second primary malignancy Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL